NexgenRx Inc.
NXG.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.37% | 8.53% | 21.67% | 17.26% | 21.90% |
| Total Other Revenue | 35.52% | -21.38% | -2.69% | 13.67% | 26.93% |
| Total Revenue | 1.59% | 7.12% | 20.64% | 17.13% | 22.06% |
| Cost of Revenue | 8.14% | -33.21% | 32.80% | 18.13% | 13.07% |
| Gross Profit | 0.04% | 19.24% | 17.27% | 16.86% | 24.41% |
| SG&A Expenses | -0.46% | -6.12% | 8.10% | 17.01% | 18.72% |
| Depreciation & Amortization | -7.48% | -3.67% | -5.41% | -5.99% | -3.19% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.80% | -11.76% | 12.03% | 14.99% | 15.24% |
| Operating Income | 7.70% | 279.44% | 246.08% | 880.95% | 126.13% |
| Income Before Tax | 8.16% | 250.00% | 181.75% | 128.21% | 155.42% |
| Income Tax Expenses | 6.47% | 396.96% | -5.66% | 1.76% | -0.59% |
| Earnings from Continuing Operations | 7.43% | 93.09% | 212.21% | 464.06% | 137.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.43% | 93.09% | 212.21% | 464.06% | 137.27% |
| EBIT | 7.70% | 279.44% | 246.08% | 880.95% | 126.13% |
| EBITDA | -2.03% | 888.50% | 124.57% | 15.77% | 47.44% |
| EPS Basic | 6.67% | 62.30% | 207.14% | 400.00% | 125.00% |
| Normalized Basic EPS | 6.90% | 252.63% | 180.00% | 150.00% | 163.64% |
| EPS Diluted | -6.67% | 64.18% | 200.00% | 400.00% | 125.00% |
| Normalized Diluted EPS | 3.57% | 252.63% | 188.89% | 150.00% | 154.55% |
| Average Basic Shares Outstanding | 0.28% | -0.09% | 0.78% | 0.83% | 0.83% |
| Average Diluted Shares Outstanding | 5.49% | -0.09% | 1.13% | 1.17% | -3.77% |
| Dividend Per Share | -- | -2.70% | -- | 0.00% | -- |
| Payout Ratio | -0.13% | -2.43% | 1.88% | 1.25% | -0.58% |